Metildigoxin indications
Oral
Cardiac arrhythmias; Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
| CrCl (ml/min) | Dosage Recommendation |
| <50 | per 1.48 m2: Dose reduction may be needed. |
Intravenous
Cardiac arrhythmias; Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Maintenance: Continue with 50-300 mcg daily by mouth in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
| CrCl (ml/min) | Dosage Recommendation |
| <50 | per 1.48 m2: Dose reduction may be needed. |
Metildigoxin dosage
Oral
Cardiac arrhythmias; Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
| CrCl (ml/min) | Dosage Recommendation |
| <50 | per 1.48 m2: Dose reduction may be needed. |
Intravenous
Cardiac arrhythmias; Heart failure
Adult: 100-600 mcg daily, depending upon desired digitalisation (usually performed over 2-4 days); larger doses are given in divided doses.
Maintenance: Continue with 50-300 mcg daily by mouth in divided doses.
Elderly: Dose reduction may be required.
Renal impairment: Dialysis: Initially, 30-50% of the usual dose.
| CrCl (ml/min) | Dosage Recommendation |
| <50 | per 1.48 m2: Dose reduction may be needed. |
Metildigoxin interactions
Effectiveness reduced by phenytoin, neomycin, sulphasalazine, kaolin, pectin, antacids and in patients receiving radiotherapy. Metoclopramide may alter the absorption of solid dosage forms of digoxin. Blood levels increased by calcium channel blockers, spironolactone, quinidine and calcium salts.
Potentially Fatal: Electrolyte imbalances such as hypokalaemia and hypomagnesemia (e.g. admin of potassium-losing diuretics, corticosteroids) can increase the risk of cardiac toxicity.
Food Interaction
Absorption delayed.
Lab Interference
May increase conc of urinary 17-hydroxycorticosteroids.
Metildigoxin side effects
Nausea, vomiting, anorexia, diarrhoea, abdominal pain, headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams, delirium, acute psychoses, hallucinations, convulsions, blurred vision, colour vision may be affected, gynaecomastia.
Potentially Fatal: Heart failure, supraventricular or ventricular arrhythmias, conduction defects.
Metildigoxin contraindications
hypersensitivity to ingredients of the product or other cardiac glycosides Increased calcium levels distinct lack of potassium poisoning with digitalis (cardiac glycosides) Abnormal slowing of the pulse (bradycardia), rapid heart beat, which the Herzkanmmer proceeds of heart rhythm disorder with disturbance of conduction between atrium and ventricle (AV block) Idiopathic hypertrophic subaortic stenosis (narrowing of the outflow tract of the left heart) Planned electrical or pharmacological restoration of normal heart rhythm Concurrent therapy with calcium supplements care with: Emphysema (lung disease in which degradation of lung tissue occurs) Severe pulmonary disease control the oxygen content of arterial blood Acute myocardial infarction myocardial inflammation Magnesium deficiency diseases with disturbances of impulse formation in the heart of Chronic pericarditis with adhesions calloused heart muscle diseases stimulus conduction disorder of the heart increased potassium levels thyroid dysfunction Insufficient kidney function with valvular accumulation of fluid in the lungs.
Active ingredient matches for Metildigoxin:
Metildigoxin
List of Metildigoxin substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| ADS Myortimo (Colombia) | |
| Beikeli (China) | |
| Bemecor (Poland) | |
| Beta Metildigoxina Vitalis (Colombia) | |
| Cardiolan (Italy) | |
| Dimekor (Serbia) | |
| Lanirapid (Japan, Spain) | |
| Lanitop (Austria, Belgium, Botswana, Bulgaria, Chile, Croatia (Hrvatska), Czech Republic, Germany, Ghana, Greece, Hong Kong, Italy, Kenya, Luxembourg, Malawi, Mauritius, Namibia, Nigeria, Portugal, Slovenia, Sudan, Tanzania, Uganda, Venezuela, Zambia, Zimbabwe) | |
| Drops; Oral; Metildigoxin 0.6 mg / ml (Roche) | |
| Injectable; Injection; Metildigoxin 0.2 mg (Roche) | |
| Solution; Oral; Metildigoxin (Roche) | |
| Tablet; Oral; Metildigoxin 0.1 mg (Roche) | |
| Tablet; Oral; Metildigoxin 0.15 mg (Roche) | |
| Lanitop 0,1 mg (Austria) | |
| Lanitop 0,15 mg (Austria) | |
| Lanitop 0,2 mg (Austria) | |
| Lanitop E (Germany) | |
| Tablet; Oral; Metildigoxin | |
| Lanitop Mite (Germany) | |
| Tablet; Oral; Metildigoxin 0.1 mg | |
| Medigox (Poland) | |
| Metildigoxin Taiyo (Japan) | |
| Miopat (Italy) | |
| Plitop (Macedonia) | |
Reviews
The results of a survey conducted on ndrugs.com for Metildigoxin are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Metildigoxin. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
